EMEA confirms withdrawal recommendation for dextropropoxyphene
This article was originally published in SRA
Executive Summary
The European Medicines Agency has recommended that all non-parenteral forms of medicines containing the analgesic dextropropoxyphene be withdrawn because their risks – particularly the possibility of fatal overdose – outweigh their benefits1.
You may also be interested in...
UK Spending £2.9bn On Seven COVID-19 Vaccines
The UK government says it is on track to vaccinate the 15 million most vulnerable people by mid-February, and that a “major study” is under way to assess the potential impact of the new UK variant on vaccine efficacy.
Coronavirus Notebook: EU To Buy 30 Million Doses Of Valneva Vaccine, Russia To Issue Compulsory License For Remdesivir
The European Medicines Agency says hacked COVID-19 vaccine data has been leaked online, and Australia’s chief medical officer defends the Oxford/AstraZeneca vaccine against scientists’ claim that it is not effective enough.
EU Biosimilar Filings, Opinions And Approvals
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: